ERBB2 and breast cancer: Our data demonstrates that lower HER2 expression by the primary tumor increased the risk for T-DXd pneumonitis suggesting the possibility that the risk for pneumonitis might be higher in HER2-low breast cancer due to more off-target delivery of the deruxtecan payload [30].